The Use of Cenobamate in Patients with Genetic Epilepsies
Abstract number :
3.418
Submission category :
7. Anti-seizure Medications / 7C. Cohort Studies
Year :
2024
Submission ID :
539
Source :
www.aesnet.org
Presentation date :
12/9/2024 12:00:00 AM
Published date :
Authors :
Presenting Author: Laura Vilella, MD – University of Texas Health Science Center at Houston
Luisa Panades de Oliveira, MD – Hospital del Mar
Alessandro Principe, MD, PhD – Hospital del Mar
Felipe Alvarez Gomez, MD – Hospital del Mar
Victoria Ros-Castelló, MD – Hospital Sant Pau, Barcelona, Spain
Alba Sierra-Marcos, MD, PhD – Epilepsy Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
Susana Boronat, MD – Hospital Sant Pau, Barcelona, Spain
Luis Perez-Jurado, MD, PhD – Hospital del Mar
Rodrigo Rocamora, MD, PhD – Hospital del Mar
Rationale: Epilepsies from genetic etiology comprise a wide phenotypic spectrum. Drug resistance is common, and patients may not be suitable candidates for resective surgery. Cenobamate is a newly approved antiseizure medication (ASM) for focal-onset seizures which has shown promising results. The aim of this study is to describe real-world experience of cenobamate in patients with genetic epilepsy (GE).
Methods: This is a multicentric, retrospective analysis of consecutive adult patients with GE (with a known pathogenic variant) receiving treatment with cenobamate. Data regarding seizure outcomes, adverse effects (AEs) and concomitant ASM were collected. Patients were considered responders when they experienced a ≥50% reduction in seizure frequency for ≥ 1 seizure type.
Results: Seven patients (five females) with a mean age of 29.3 years (range 21-47) were included. All patients, except one, had intellectual disability. One patient had failed resective surgery and two patients had a VNS implanted. The mean duration of treatment with cenobamate was 10.4 months (range 3-23) and the median dose at last follow up was 200 mg (range 25-400 mg). The responder rate was 57.1%, and response was seen in all patients experiencing tonic seizures leading to falls (Table 1). AEs were reported by five patients. Drowsiness was the most common AE, reported by half of the patients, but it lead to discontinuation of cenobamate in only one of them. Three patients had ≥ 1 ASM discontinued and one patient had dose reduction of ≥ 1 ASM (Table 2).
Conclusions: Cenobamate offers encouraging responder rates in patients with GE and may be particularly helpful for those with tonic seizures leading to falls. AE are common and require frequent adjustment of co-medications.
Funding: None
Anti-seizure Medications